Fresh momentum is building in Europe’s venture capital space as Vi Partners gears up for its next phase of growth.
The Altendorf, Switzerland-based firm has just reached an important milestone, signaling that it’s ready to put new money to work and deepen its footprint across technology and healthcare.
First Closing Marks a Strong Start
Vi Partners has successfully completed the first closing of its newest venture capital fund, which is aiming to raise a total of CHF150 million.
With this initial close secured, the firm is officially in deployment mode and preparing to back its next wave of startups.
More closings are expected as the year unfolds, suggesting continued interest from investors and steady progress toward the fund’s full target.
Early-Stage and Series A at the Core
This new fund keeps Vi Partners firmly focused on what it does best: supporting companies at the Series A and early-stage levels.
The strategy centers on identifying ambitious founders early and helping them scale with both capital and hands-on expertise.
The investment scope spans two major sectors—technology and healthcare—where the firm has already built a strong track record.
Backing Mission-Critical Technology
On the technology side, Vi Partners is targeting companies that are developing essential software and data-driven platforms.
These are businesses solving real operational problems, particularly across enterprise software, artificial intelligence, fintech, and industrial technology.
The emphasis is on solutions that organizations rely on every day, rather than experimental or short-term trends.
Tackling Real Needs in Healthcare
Healthcare remains a major pillar of the new fund.
Vi Partners plans to support startups that address meaningful clinical challenges and inefficiencies within healthcare systems.
Its focus areas include biotech, medtech, and digital health—sectors where innovation can directly improve patient outcomes, reduce costs, or streamline care delivery.
A Strategy Built on Proven Success
This investment approach builds on Vi Partners’ history as an early backer of notable companies.
In healthcare, the firm has supported names such as AMAL Therapeutics, Kuros Biosciences, Araris Biotech, and Oculis.
On the technology side, its portfolio includes companies like Nexthink, SumUp, and Unique.
These past successes reinforce the firm’s confidence in doubling down on early-stage opportunities across both sectors.
Leadership Steering the Vision
The fund is led by an experienced management team with deep roots in venture investing:
- Gaetano Zanon, Managing Partner
- Diego Braguglia, Managing Partner
- Olivier Laplace, Managing Partner
Together, they bring a blend of strategic insight, operational experience, and long-term commitment to founder partnerships.
What’s Next?
With capital now ready to be deployed, Vi Partners is expected to become increasingly active in deal-making over the coming months.
As additional closings take place, the firm’s investment pace is likely to accelerate—setting the stage for a new generation of tech and healthcare startups to emerge from its portfolio.
Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn